DPP 4 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers DPP4 Inhibitors Drugs & Brand Names and the Market is Segmented Into Drugs (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia (Alogliptin), Galvus (Vildagliptin) and Others), And Geography (North America, Europe, Asia-pacific, Middle East and Africa, And Latin America). The Market Provides the Value (in USD) and Volume (in Units) for the Above-Mentioned Segments.

DPP 4 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 11.91 Billion
Market Size (2030) USD 13.66 Billion
CAGR (2025 - 2030) 2.78 %
Fastest Growing Market Latin America
Largest Market Asia-Pacific
Market Concentration Medium

Major Players

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Dipeptide Peptidase 4 (DPP-4) Inhibitors Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis

The Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 11.91 billion in 2025, and is expected to reach USD 13.66 billion by 2030, at a CAGR of 2.78% during the forecast period (2025-2030).

The COVID-19 pandemic positively impacted the Dipeptide Peptidase 4 (DPP-4) Inhibitors Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. In the current crisis, type 2 diabetes patients are at much higher risk.

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.

According to International Diabetes Federation (IDF), the adult diabetes population is approximately 537 million currently, and this number is going to increase by 643 million in 2030. Technological advancements have increased over the period leading to several modifications either in the DPP-4 Inhibitor drugs or the formulations being developed.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Overview

The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is fragmented, with manufacturers like AstraZeneca, Merck, Boehringer Ingelheim, Novartis, etc., gaining presence in major countries. At the same time, the remaining market comprises other local or region-specific manufacturers.

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Leaders

  1. Merck

  2. AstraZeneca

  3. Boehringer Ingelheim Pharmaceuticals Inc.

  4. Pfizer Inc.

  5. Eli Lilly and Company

  6. *Disclaimer: Major Players sorted in no particular order
Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market News

  • February 2023: The Indian government's National Pharmaceutical Pricing Authority (NPPA) fixed the retail prices of 74 medicines, including diabetes, high blood pressure, etc. As per the notification by the NPPA, the cost of one tablet of Dapagliflozin Sitagliptin and Metformin Hydrochloride (Extended-Release Tablet) is fixed at INR 27.75 (USD 0.34).
  • July 2022: Glenmark Pharmaceuticals Limited announced that it launched sitagliptin and its Fixed Dose Combinations for adults with Type 2 diabetes in India. Glenmark introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at an affordable price.

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Drugs
    • 5.1.1 Januvia (Sitagliptin)
    • 5.1.2 Onglyza (Saxagliptin)
    • 5.1.3 Tradjenta (Linagliptin)
    • 5.1.4 Vipidia (Alogliptin)
    • 5.1.5 Galvus (Vildagliptin)
    • 5.1.6 Others
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Rest of North America
    • 5.2.2 Europe
    • 5.2.2.1 France
    • 5.2.2.2 Germany
    • 5.2.2.3 Italy
    • 5.2.2.4 Spain
    • 5.2.2.5 United Kingdom
    • 5.2.2.6 Russia
    • 5.2.2.7 Rest of Europe
    • 5.2.3 Latin America
    • 5.2.3.1 Mexico
    • 5.2.3.2 Brazil
    • 5.2.3.3 Rest of Latin America
    • 5.2.4 Asia-Pacific
    • 5.2.4.1 Japan
    • 5.2.4.2 South Korea
    • 5.2.4.3 China
    • 5.2.4.4 India
    • 5.2.4.5 Australia
    • 5.2.4.6 Vietnam
    • 5.2.4.7 Malaysia
    • 5.2.4.8 Indonesia
    • 5.2.4.9 Philippines
    • 5.2.4.10 Thailand
    • 5.2.4.11 Rest of Asia-Pacific
    • 5.2.5 Middle East and Africa
    • 5.2.5.1 Saudi Arabia
    • 5.2.5.2 Iran
    • 5.2.5.3 Egypt
    • 5.2.5.4 Oman
    • 5.2.5.5 South Africa
    • 5.2.5.6 Rest of Middle East and Africa

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Merck And Co.
    • 7.1.2 AstraZeneca
    • 7.1.3 Bristol Myers Squibb
    • 7.1.4 Novartis
    • 7.1.5 Takeda Pharmaceuticals
    • 7.1.6 Eli Lilly and Company
    • 7.1.7 Boehringer Ingelheim
    • 7.1.8 Pfizer
    • 7.1.9 GlaxoSmithKline
  • *List Not Exhaustive
  • 7.2 Company Share Analysis
    • 7.2.1 Merck And Co.
    • 7.2.2 AstraZeneca
    • 7.2.3 Takeda Pharmaceuticals
    • 7.2.4 Novartis
    • 7.2.5 Others

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Segmentation

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a pharmacological class of drugs for treating Type 2 diabetes. They help to control glycemia by increasing the levels of active incretins. The Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is segmented into drugs and geography. The report offers the value (in USD) and volume (in units) for the above segments. 

Drugs Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia (Alogliptin)
Galvus (Vildagliptin)
Others
Geography North America United States
Canada
Rest of North America
Europe France
Germany
Italy
Spain
United Kingdom
Russia
Rest of Europe
Latin America Mexico
Brazil
Rest of Latin America
Asia-Pacific Japan
South Korea
China
India
Australia
Vietnam
Malaysia
Indonesia
Philippines
Thailand
Rest of Asia-Pacific
Middle East and Africa Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Research FAQs

How big is the Dipeptide Peptidase 4 Inhibitors Market?

The Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 11.91 billion in 2025 and grow at a CAGR of 2.78% to reach USD 13.66 billion by 2030.

What is the current Dipeptide Peptidase 4 Inhibitors Market size?

In 2025, the Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 11.91 billion.

Who are the key players in Dipeptide Peptidase 4 Inhibitors Market?

Merck, AstraZeneca, Boehringer Ingelheim Pharmaceuticals Inc., Pfizer Inc. and Eli Lilly and Company are the major companies operating in the Dipeptide Peptidase 4 Inhibitors Market.

Which is the fastest growing region in Dipeptide Peptidase 4 Inhibitors Market?

Latin America is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Dipeptide Peptidase 4 Inhibitors Market?

In 2025, the Asia-Pacific accounts for the largest market share in Dipeptide Peptidase 4 Inhibitors Market.

What years does this Dipeptide Peptidase 4 Inhibitors Market cover, and what was the market size in 2024?

In 2024, the Dipeptide Peptidase 4 Inhibitors Market size was estimated at USD 11.58 billion. The report covers the Dipeptide Peptidase 4 Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Dipeptide Peptidase 4 Inhibitors Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

DPP 4 Inhibitors Industry Report

Statistics for the 2025 Dipeptide Peptidase 4 (DPP-4) Inhibitors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Dipeptide Peptidase 4 (DPP-4) Inhibitors analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.